Skip to main content

Actavis goes up for sale, peaks interest of major Rx companies


NEW YORK Icelandic generic drug maker Actavis is for sale and could go for up to $10.8 billion at a time when many generic drug companies find themselves targets of acquisitions.

The fifth largest maker of generic drugs in the world, Actavis became a private company in 2007 after action by majority stakeholder Novator, led by Icelandic billionaire Thor Bjorgolfsson.

According to Reuters, a number of large drug makers could end up buying the company, including Pfizer, Sanofi-Aventis, GlaxoSmithKline and Novartis.

In other news, the Food and Drug Administration announced Friday that it had filed a consent decree and was awaiting the United States District Court for the District of New Jersey’s entry of a permanent injunction forbidding Actavis’ U.S. subsidiary, Actavis Totowa, from manufacturing drugs in its New Jersey factories until the FDA decides the factories are in compliance with current good-manufacturing practice requirements.

This ad will auto-close in 10 seconds